Can Trastuzumab Duration Be Shortened in HER2-Positive Breast Cancer?
The Short-HER study was unable to show noninferiority of 9 weeks of trastuzumab compared with the standard 1 year in women with HER2-positive breast cancer.
How Does Hormonal Contraceptive Use Affect Ovarian Cancer Risk?
A study shows that combined hormonal contraceptive use is associated with a significant reduction in the risk of ovarian cancer.
Is Axillary Dissection Necessary in Early Breast Cancer?
Nearly 10 years of follow-up from a large clinical trial have confirmed that axillary dissection is not necessary in patients with early breast cancer.
BRAF-MEK Inhibitor Combo Extends Survival in BRAF-Mutant Melanoma
The combination of encorafenib and binimetinib resulted in longer overall survival compared with vemurafenib in patients with BRAF V600–mutant melanoma.
Are Stromal Cells Mediating Response to Immunotherapy in Bladder Cancer?
New research suggests that immune resistance in urothelial cancer may be mediated by stromal cells, which act as a source of EMT-related gene expression.
Biomarker Associated With Longer Survival Uncovered in Ovarian Cancer
A new proteomic analysis found that CT45 is an independent prognostic factor in patients with high-grade serous ovarian cancer, and a potential target of immunotherapies.
Can Pancreastatin Levels Guide Therapy in NETS Patients Undergoing TACE?
For patients with NETs that have metastasized to the liver, high levels of serum pancreastatin are predictive of poor outcomes after treatment with TACE.
Do Dose-Dense Neoadjuvant Chemo Regimens Improve Responses in Bladder Cancer?
A dose-dense neoadjuvant chemotherapy regimen yielded higher response rates compared with a standard regimen in a cohort of bladder cancer patients.
Advances in Breast Cancer Survival Have Plateaued in the Last Decade
Survival has increased substantially for young women with breast cancer since 1975, though it has largely reached a plateau since around 2005.
Cytokine Molecule Could Offer Prognostic Guidance in Lung NETs
A new study suggests that the cytokine CXCL12 could be useful as a prognostic biomarker in patients with neuroendocrine tumors of the lung.
Mitochondrial Protein Offers Potentially Novel Target for HER2+ Breast Cancer
A new laboratory study has shed some light on how mitochondrial metabolism is altered in breast cancer.
Does Sequential vs Concurrent Treatment Change Outcomes in HER2+ Breast Cancer?
Outcomes for patients with HER2-positive breast cancer did not differ when treated with sequential chemotherapy plus trastuzumab compared with a concurrent approach.
Could Adding a TLR9 Agonist Improve Responses in Metastatic Melanoma?
The combination of pembrolizumab and a TLR9 agonist known as SD-101 showed promising activity in patients with unresectable or metastatic melanoma.
CTC Gene Signature Score Could Guide Breast Cancer Treatment Decisions
A 17-gene signature derived from circulating tumor cells was found to correlate with response to therapy in patients with breast cancer.
Could Active Surveillance Help Prevent Advanced Melanoma in CLL Patients?
Active surveillance could help lead to early excision of melanoma, and thus better outcomes, in patients with CLL.
PARP Inhibitor Offers Improved Quality of Life in Advanced Breast Cancer
Treatment with talazoparib improved quality of life vs physician’s choice of chemotherapy in patients with HER2-negative advanced breast cancer.
Screening for Neuroendocrine Tumors Is Recommended for NF1 Patients
A study on pheochromocytoma and paraganglioma associated with neurofibromatosis type 1 highlights how screening for these malignancies is important.
Sorafenib Offers Survival Improvements in Ovarian Cancer
Sorafenib combined with topotecan and then continued as maintenance therapy offered a significant improvement in survival outcomes in women with platinum-resistant ovarian cancer.
Can Simple Clinical Factors Predict Metastatic Potential of Neuroendocrine Tumors?
Researchers have developed a clinical prediction model for the metastatic potential of pheochromocytoma and paraganglioma.
Apatinib/Etoposide Promising in Platinum-Resistant Ovarian Cancer
Apatinib combined with etoposide offers promising efficacy in patients with platinum-resistant ovarian cancer.
Baseline Factors Linked With Outcome in BRAF-Mutant Melanoma
Baseline levels of lactate dehydrogenase are significantly associated with progression-free survival outcomes in patients with BRAF V600–mutated metastatic melanoma.
Locoregional Recurrence Rates Vary Based on Several Factors in Bladder Cancer
A meta-analysis identified several factors that are correlated with locoregional recurrence in patients with nonmetastatic muscle-invasive bladder cancer.
Several Genetic Variants Associated With Increased TNBC Risk
A study using multigene panel testing identified several pathogenic variants associated with an increased risk of triple-negative breast cancer.
Could HER2 Amplification Aid in the Prognosis of HER2-Positive Breast Cancer?
The presence of HER3 expression and a high HER2/CEP17 ratio distinguish a group of invasive HER2-positive ductal breast cancer patients who have a worse prognosis.
Hurdles Remain for Lung Cancer Screening Programs
Low-dose CT screening for lung cancer is recommended for certain individuals, but two new studies highlight some of the limitations and growing pains of a screening program.
Is Marital Status Associated With Bladder Cancer Outcome?
An existing body of literature shows that marital status and related social support are connected with disease outcomes.
Adding TKIs Could Increase Responses in Metastatic HER2+ Breast Cancer
A laboratory study found that combining anti-HER2 TKIs with trastuzumab and pertuzumab can result in enhanced anticancer activity in HER2+ breast cancer cell lines.
Cardiac Surveillance in Breast Cancer Survivors Who Received IMC Radiation?
Internal mammary chain radiation therapy for breast cancer is associated with increased cardiac toxicity, in particular when paired with anthracyclines.
Are Clinicians Discussing Financial Toxicity With Breast Cancer Patients?
Many breast cancer patients report that clinicians do not engage adequately regarding management of financial toxicity associated with their diagnosis, according to a new survey.
Adjuvant Bevacizumab Fails to Help in High-Risk Breast Cancer
The addition of bevacizumab to adjuvant chemotherapy regimens does not improve survival in women with high-risk breast cancer.